Summary Epidemiological and experimental studies suggest that dehydroepiandrosterone (DHEA) exerts a protective effect against breast cancer. It has been proposed that the non-competitive inhibition of glucose-6-phosphate dehydrogenase (G6PD) contributes to DHEA antitumour action. We evaluated the effects of DHEA on G6PD activity and on the in vitro proliferation of two human breast cancer cell lines, MCF-7 (steroid receptor positive) and MDA-MB-231 (steroid receptor negative), in a serum-free assay. DHEA inhibition of G6PD was only found to occur at concentrations above 10 gm; at these high concentrations, the growth curve was parallel to the enzyme inhibition curve in both cell lines. In contrast, at concentrations in the in vivo breast tissue concentration range, neither cell growth nor enzyme activity was inhibited. The results failed to confirm DHEA's putative anti-tumour action on breast cancer through G6PD inhibition, as the enzyme blockade only becomes apparent at pharmacological concentrations of the steroid.
INTRODUCTION
Epidemiological studies in premenopausal women show that plasma and urine levels of dehydroepiandrosterone (DHEA) and its sulphated metabolite (DHEAS) are inversely related to breast cancer risk, suggesting a protective effect of DHEA against breast cancer (Bulbrook et al, 1962 (Bulbrook et al, , 1971 Brownsey et al, 1972; Wang et al, 1974 , Rose et al, 1977 Zumoff et al, 1981) . Moreover, DHEA administration in rodents blocks the development of both spontaneous and carcinogen-induced tumours of various organs, including the mammary gland (Schwartz, 1979; Schwartz and Tannen, 1981; Schwartz et al, , 1986 Pashko et al., 1984 Pashko et al., , 1985 Moore et al, 1986a,b; Boccuzzi et al, 1992a) . DHEA effect on breast cancer growth may depend on its hormonal activity via steroid receptors (SR), as DHEA is metabolized in breast tissue to 5-en-androstene-3 P, 17 ,-diol (ADIOL), a compound with both oestrogenic and androgenic properties (Poortman et al, 1975; Hackenberg et al, 1993) . However, the prevailing hormonal activity of DHEA is to stimulate cell growth via the oestrogen receptors (ERs) (Adams et al, 1981; Najid and Habrioux, 1990; Pizzini et al, 1992) , whereas its antiproliferative effect, due to androgen receptor (AR) binding (Hackemberg et al, 1993) , becomes appreciable only when ERs are blocked (Boccuzzi et al, 1993 (Boccuzzi et al, , 1994 . Besides the SR-mediated effects, DHEA has been shown to exert numerous activities in both physiological and pathological conditions via 'non-hormonal' mechanism(s) (Ebeling and Koivisto, 1994) . The inhibition of glucose-6-phosphate dehydrogenase (G6PD) activity by DHEA has been claimed to play a major role in preventing carcinogenesis, as well as exerting an anti-obesity action in rats (Schwartz et al, 1988; Cleary 1991; Schwartz and Pashko, 1993) . The inhibition of the G6PD pathway (Benes and Oertel, 1971; Feo et al, 1987 ) might explain the protective action of DHEA against breast cancer (Schwartz et al, 1988) . In agreement with this hypothesis, it has been reported that breast cancer risk is reduced in G6PD-deficient women (Feo et al, 1984 (Feo et al, , 1987 . To differentiate between SR-dependent and SRindependent actions of DHEA on breast cancer cell growth, we used a serum-free assay to evaluate G6PD activity in MDA-MB-231 (hormone unresponsive) and in MCF-7 (hormone-responsive) breast cancer cell lines cultured in the presence of DHEA.
MATERIALS AND METHODS
Dehydroepiandrosterone (DHEA) (Sigma Chemicals, USA) was diluted in ethanol; the final concentration of ethanol in the medium did not exceed 0.1% and had no detectable effect on cell growth. Nevertheless, the same concentration of ethanol was added to the control culture medium.
Fetal calf serum (FCS) (Eurobio, France) was extracted with charcoal dextran (10:1), to remove steroids, at 25°C for 60 min. The serum-free medium comprised: RPMI-1640 phenol red-free medium (Sigma Chemicals) plus 2mM L-glutamine (Eurobio, France), 100 IU ml penicillin G, 100 gg mll streptomycin, 2 mg 1-' human transferrin (Sigma Chemicals) and 20 mM Hepes buffer (Sigma Chemicals). MCF-7 (oestrogen, progesterone and androgen receptor positive) and MDA-MB-231 (oestrogen, progesterone and androgen receptor negative) cell lines were from the American Type Culture Collection (USA); cells were routinely cultured in 25-cm2 plastic flasks (Falcon, USA) in RPMI-1640 phenol red-free medium plus 10% FCS. The cells were grown in a allowed to attach for 24 h in the medium supplemented with 10% steroid-stripped FCS. The seeding medium was then replaced with a serum-free medium containing DHEA (0.05-50 tM). Control cells were grown in steroid-free medium. The medium was renewed on the fourth day. Cells in the exponential growth phase were harvested by trypsin 7 days after plating and counted (twice for each well) in a Burker's chamber. G6PD activity was measured using the Glock and McLean assay (Glock and McLean, 1953) . Equal numbers of cells for each condition were suspended in Tris 0.1 M (7.5 x 104 cells per 50 ,ul) and homogenized in bursts of 3-5 s in a Polytron PT1O, with 30 s cooling in ice between bursts.
The homogenates were centrifuged (4°C) at 70 000 g for 60 min.
The lower layer (20 tl) was incubated at 37°C for 10 min with 930 ,ul of Tris 0.1 M buffer plus NADP (3.5 mg ml-') and magnesium chloride (0.5 M). At time zero, the reaction substrate was added (50 ,tl of 3.38 mg ml-' glucose 6-phosphate and/or 50 tl of 4.75 mg ml-' 6-phosphogluconate). The amount of NADP reduction was calculated at 15-min intervals throughout a 3 h period as variation of absorbance at 366 nm and at 37°C.
RESULTS
The effect of different concentrations of DHEA (0.05-50 gM) on the growth of MCF-7 and MDA-MB-23 1 cells is shown in Figure  1 . At low concentrations (in the range of those found in breast tissue) (van Landeghem et al, 1985) , DHEA only modified the growth of hormone-responsive MCF-7 cells; on day 7 of culture, growth of MCF-7 cells was stimulated, whereas no effect on the proliferation of hormone-unresponsive MDA-MB-231 cells was detectable. Conversely, at high concentrations (20-50 ,UM), the effect of DHEA appeared not to be influenced by steroid receptor availability; the effect exerted on cell growth of the two cell lines was similar, growth inhibition of the same amplitude being produced. G6PD activity was measured in cell homogenates in the presence of increasing concentrations of DHEA (0.05-50 ,UM). Enzyme activity in the two cell lines is shown in Figure 2 ; no inhibition was detectable for DHEA concentrations up to 5 ,UM, whereas a dose-dependent inhibition was observed at concentrations above 10 ,UM. The effect on enzyme activity was similar in the two cell lines.
DISCUSSION
Results show that DHEA, at concentrations considerably above those found in vivo in breast tissue (van Landeghem et al, 1985) , inhibits both G6PD activity and cell growth. Previous research has failed to demonstrate any inhibitory effect of DHEA on breast cancer cell growth in vitro (Poulin and Labrie, 1986; Boccuzzi et al, 1993) . However, the putative inhibition of cell growth via G6PD blockade may have not been evident because of the presence of serum in the culture medium; serum (fetal calf derived) can mask the antiproliferative action of G6PD inhibition (Dworkin et al, 1986) , probably because of its high nucleoside content (Feo et al, 1991; Pashko et al, 1991) . Moreover, the use of a hormoneresponsive cell line obscures the mechanism of the action on cell growth because of the overlap of hormonal and non-hormonal effects. More precisely, the proliferative effects of DHEA that are due to ER binding of its metabolite ADIOL (Adams et al, 1981; Najid and Habrioux, 1990 ) may mask an antiproliferative action because of G6PD inhibition. In view of this, we evaluated DHEA DHEA and G6PD in breast cancer cells 591 action on G6PD activity and growth in both SR-negative and SRpositive cells. Nucleoside interference was avoided by using a serum-free assay. Data show that, as DHEA concentrations increase, the growth curve parallels the enzyme inhibition curve. This effect probably depends on the reduced availability of ribose phosphate, resulting in reduced DNA synthesis (Dworkin et al, 1986; Feo et al, 1991; Pashko et al, 1991) . However, the inhibitory effect is appreciable only for DHEA concentrations well above those found in vivo in breast tissue. At these high DHEA concentrations, SR expression does not influence the effect on the growth of the two cell lines. While high DHEA concentrations exert an effect on both growth and G6PD activity that is similar in the two cell lines, the effect of DHEA at concentrations found in vivo in breast tissue is conditioned by SR expression. Neither G6PD activity nor cell growth is affected by DHEA in SR-cells; conversely, the growth of the SR+ cells is stimulated by DHEA, but G6PD activity is not affected. The stimulatory action of DHEA on cell growth depends on its metabolization to ADIOL, a compound which binds to ERs (Adams et al, 1981; Najid and Habrioux, 1990; Boccuzzi et al, 1992b , Pizzini et al, 1992 . This result does not support the theory that DHEA plays a role in the growth of breast cancer through G6PD modulation. The reports that suggest that DHEA inhibition of G6PD explains DHEA's protective effect against mammary cancer growth in rodents comprised prolonged treatment with pharmacological doses of the steroid (Schwartz et al, 1988; Schwartz and Pashko, 1993) . Our in vitro model demonstrates that only the hormonal properties of DHEA are appreciable when the steroid is tested at concentrations found in breast tissue. The action on the enzyme would appear to be pharmacological in nature.
